Stephane L Bogen

USPTO Granted Patents = 47 (Patent Applications = 11)

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 24 (Patent Applications = 15)

Average Co-Inventor Count = 10.1

ph-index = 13

Forward Citations = 496(Granted Patents)

Location History:

Rahway, NJ (US) (2019)
Somerset, NJ (US) (2004 - 2023)

Company Filing History:

25 out of 2,405

Merck Sharp + Dohme Corp.

Idenix Pharmaceuticals, Inc.

patents

6. 1 out of 7

Msd International Gmbh

patents

7. 1 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 2004-2025

Loading Chart...

47 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12331018 - Pyrrolidine orexin receptor agonists (2025-06-17),

2. 12312332 - Heteroaryl pyrrolidine and piperidine orexin receptor agonists (2025-05-27),

3. 11730748 - Cyclic phosphate substituted nucleoside derivatives for the treatment of liver diseases (2023-08-22),

4. 11680060 - Bicycloheptane pyrrolidine orexin receptor agonists (2023-06-20),

5. 11098029 - 5-alkyl pyrrolidine orexin receptor agonists (2021-08-24),

6. 10899788 - Cyclic phosphate substituted nucleoside compounds and methods of use thereof for the treatment of viral diseases (2021-01-26),

7. 10508108 - Tricyclic compounds as inhibitors of mutant IDH enzymes (2019-12-17),

8. 10442819 - Tricyclic compounds as inhibitors of mutant IDH enzymes (2019-10-15),

9. 10399972 - Tricyclic compounds as inhibitors of mutant IDH enzymes (2019-09-03),

10. 10086000 - Tricyclic compounds as inhibitors of mutant IDH enzymes (2018-10-02),

11. 9765107 - Cyclic phosphonate substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases (2017-09-19),

12. 9732111 - 2'-alkynyl substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases (2017-08-15),

13. 9637493 - Substituted pyrrolopyrimidines as HDM2 inhibitors (2017-05-02),

14. 9540377 - 2,6,7,8 substituted purines as HDM2 inhibitors (2017-01-10),

15. 9457039 - 2'-disubstituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases (2016-10-04),

Title: The Innovative Journey of Inventor Stephane L Bogen

Introduction:

Stephane L Bogen is a prolific inventor based in Somerset, NJ (US) with an impressive portfolio of 45 patents to his name. His groundbreaking work has significantly impacted the fields of pharmaceuticals and neurology.

Latest Patents:

Two of Stephane L Bogen's latest patents showcase his ingenuity and contribution to the medical world. The first patent pertains to 'Cyclic phosphate substituted nucleoside derivatives for the treatment of liver diseases', focusing on compounds that have promising therapeutic potential. The second patent revolves around 'Bicycloheptane pyrrolidine orexin receptor agonists', offering hope for the treatment of neurological and psychiatric disorders.

Career Highlights:

Stephane L Bogen has made substantial contributions during his tenure at esteemed companies such as Merck Sharp & Dohme Corporation and Schering Corporation. His innovative spirit and dedication to research have led to significant advancements in the pharmaceutical industry.

Collaborations:

Throughout his career, Stephane L Bogen has collaborated with notable individuals in the field. F George Njoroge and Frank W Bennett are among his esteemed coworkers, with whom he has worked on pioneering projects that have shaped the landscape of medical research.

Conclusion:

In conclusion, Stephane L Bogen stands out as a visionary inventor whose work continues to make a profound impact on the healthcare industry. His dedication to innovation and relentless pursuit of groundbreaking solutions underscore his position as a trailblazer in the field of pharmaceuticals and neurology.

This text is generated by artificial intelligence and may not be accurate.